Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Michael R Migden"'
Autor:
Ruth Plummer, Ralf Gutzmer, Anne Lynn S. Chang, John T. Lear, Martin Kaatz, Uwe Trefzer, Alexandros Stratigos, Carmen Loquai, Luc Dirix, Patrick Combemale, Nicholas Squittieri, Karl D. Lewis, Reinhard Dummer, Michael R. Migden, A Guminksi, Ragini R. Kudchadkar, H.-J. Schulze
Publikováno v:
British Journal of Dermatology. 182:1369-1378
Background: Basal cell carcinomas (BCCs) exhibit aberrant activation of the hedgehog pathway. Sonidegib is a hedgehog pathway inhibitor approved for the treatment of locally advanced BCC (laBCC) and metastatic BCC (mBCC) based on primary results of t
Publikováno v:
Future Oncology. 12:2095-2105
The Hedgehog inhibitors are promising alternative for patients with advanced basal cell carcinoma that are not amenable to radiotherapy or surgery. Sonidegib, also known as LDE225, is an orally available SMO antagonist that was recently approved by t
Publikováno v:
Future oncology (London, England). 14(6)
Sonidegib, a hedgehog pathway inhibitor, was approved by the US FDA for the treatment of locally advanced basal cell carcinoma which cannot be readily treated with surgery or radiotherapy. The pharmacology and pharmacokinetics of sonidegib will be di
Autor:
Karl D. Lewis, Michael R. Migden
Publikováno v:
Journal of Clinical Oncology. 36:9573-9573
9573Background: Sonidegib is a hedgehog pathway inhibitor (HPI) approved for the treatment of locally advanced basal cell carcinoma (laBCC) not amenable to curative surgery or radiotherapy. Patient...
Autor:
Patrick Combemale, Elizabeth Ruth Plummer, Carmen Loquai, Anne Lynn S. Chang, Michael R. Migden, Ragini R. Kudchadkar, Karl D. Lewis, Ralf Gutzmer, Uwe Trefzer, Tingting Yi, Luc Dirix, Dalila Sellami, John T. Lear, Henry Castro, Reinhard Dummer, Martin Kaatz, Manisha Mone, Alexander Guminski, Alexander J. Stratigos
Publikováno v:
Journal of Clinical Oncology. 34:9538-9538
9538Background: Sonidegib 200 mg was approved for use in pts with advanced BCC (aBCC; laBCC + mBCC) or laBCC not amenable to surgery/radiotherapy based on results from BOLT (NCT01327053). Updated d...